Literature DB >> 12865777

Use of epinephrine in the treatment of anaphylaxis.

Phil Lieberman1.   

Abstract

PURPOSE OF REVIEW: This paper is intended to review recent literature that impacts the use of epinephrine in the therapy of anaphylaxis. RECENT
FINDINGS: The most important recent finding regarding the administration of epinephrine is that the intramuscular route of administration is the route of choice for the treatment of anaphylaxis, and the lateral aspect of the thigh is the site of choice. In addition, recent research emphasizes the fact that epinephrine is grossly underused in the management of anaphylaxis, which accentuates the need for further education of both physician and patient in this regard.
SUMMARY: Several major themes have emerged from this review of the recent literature. The finding that the intramuscular route of administration for epinephrine is superior has now been recognized by the guidelines, and because the site of choice has been found to be the lateral aspect of the thigh, the needle used for injection must be long enough to penetrate the vastus lateralis muscle. The reasons for the underutilization of epinephrine in the treatment of anaphylaxis are also discussed. Other important findings include the fact that outdated EpiPens can usually be administered safely, and alternative routes of administration, which may be more acceptable to patients, may be on the horizon as a result of preliminary studies assessing the administration of sublingual epinephrine by wafer. Finally, it is now understood that epinephrine prescription data may be one of our best tools to study the epidemiology and incidence of anaphylactic episodes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12865777     DOI: 10.1097/00130832-200308000-00013

Source DB:  PubMed          Journal:  Curr Opin Allergy Clin Immunol        ISSN: 1473-6322


  9 in total

Review 1.  Clinical pharmacology, uses, and adverse reactions of iodinated contrast agents: a primer for the non-radiologist.

Authors:  Jeffrey J Pasternak; Eric E Williamson
Journal:  Mayo Clin Proc       Date:  2012-04       Impact factor: 7.616

2.  Fast-disintegrating sublingual tablets: effect of epinephrine load on tablet characteristics.

Authors:  Mutasem M Rawas-Qalaji; F Estelle R Simons; Keith J Simons
Journal:  AAPS PharmSciTech       Date:  2006-04-28       Impact factor: 3.246

3.  Determination of the enantiomeric purity of epinephrine by HPLC with circular dichroism detection.

Authors:  Douglas Kirkpatrick; Jingyue Yang; Michael Trehy
Journal:  J Liq Chromatogr Relat Technol       Date:  2017-05-31       Impact factor: 1.312

4.  Acute treatment of anaphylaxis in children.

Authors:  Ran D Goldman
Journal:  Can Fam Physician       Date:  2013-07       Impact factor: 3.275

5.  Acute adverse drug reactions following cardiac catheterization: evidence-based guidance for providers and systems.

Authors:  Spencer W Trooboff; Alexander Iribarne
Journal:  J Thorac Dis       Date:  2019-07       Impact factor: 2.895

6.  World allergy organization guidelines for the assessment and management of anaphylaxis.

Authors:  F Estelle R Simons; Ledit R F Ardusso; M Beatrice Bilò; Yehia M El-Gamal; Dennis K Ledford; Johannes Ring; Mario Sanchez-Borges; Gian Enrico Senna; Aziz Sheikh; Bernard Y Thong
Journal:  World Allergy Organ J       Date:  2011-02-23       Impact factor: 4.084

7.  The acute and long-term management of anaphylaxis: protocol for a systematic review.

Authors:  Sangeeta Dhami; Sukhmeet S Panesar; Tamara Rader; Antonella Muraro; Graham Roberts; Margitta Worm; Aziz Sheikh
Journal:  Clin Transl Allergy       Date:  2013-04-10       Impact factor: 5.871

8.  Epinephrine: the drug of choice for anaphylaxis-a statement of the world allergy organization.

Authors:  Stephen F Kemp; Richard F Lockey; F Estelle R Simons
Journal:  World Allergy Organ J       Date:  2008-07       Impact factor: 4.084

Review 9.  Pathophysiology of food-induced anaphylaxis.

Authors:  Heather Lemon-Mulé; Anna Nowak-Wegrzyn; Cecilia Berin; Adina K Knight
Journal:  Curr Allergy Asthma Rep       Date:  2008-05       Impact factor: 4.919

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.